Jung, Young-Hwan Kim, Yeo Ok Kang, Koon Mook Lee, Hyung Gon Son, Borum Han, Xuehao Oh, Eunseok Kim, Siwon Seo, Seon Hee Park, Jong-Hyun Park, Ki Duk Kim, Woong Mo Yoon, Myung Ha Kim, Yong-Chul 2024-01-19T12:03:57Z 2024-01-19T12:03:57Z 2022-06-17 2022-04 1424-8247 https://pubs.kist.re.kr/handle/201004/115280 Neuropathic pain is a chronic and sometimes intractable condition caused by lesions or diseases of the somatosensory nervous system. Many drugs are available but unfortunately do not provide satisfactory effects in patients, producing limited analgesia and undesirable side effects. Thus, there is an urgent need to develop new pharmaceutical agents to treat neuropathic pain. To date, highly specific agents that modulate a single target, such as receptors or ion channels, never progress to the clinic, which may reflect the diverse etiologies of neuropathic pain seen in the human patient population. Therefore, the development of multifunctional compounds exhibiting two or more pharmacological activities is an attractive strategy for addressing unmet medical needs for the treatment of neuropathic pain. To develop novel multifunctional compounds, key pharmacophores of currently used clinical pain drugs, including pregabalin, fluoxetine and serotonin analogs, were hybridized to the side chain of tianeptine, which has been used as an antidepressant. The biological activities of the hybrid analogs were evaluated at the human transporters of neurotransmitters, including serotonin (hSERT), norepinephrine (hNET) and dopamine (hDAT), as well as mu (mu) and kappa (kappa) opioid receptors. The most advanced hybrid of these multifunctional compounds, 17, exhibited multiple transporter inhibitory activities for the uptake of neurotransmitters with IC50 values of 70 nM, 154 nM and 2.01 mu M at hSERT, hNET and hDAT, respectively. Additionally, compound 17 showed partial agonism (EC50 = 384 nM) at the mu-opioid receptor with no influence at the kappa-opioid receptor. In in vivo pain animal experiments, the multifunctional compound 17 showed significantly reduced allodynia in a spinal nerve ligation (SNL) model by intrathecal administration, indicating that multitargeted strategies in single therapy could considerably benefit patients with multifactorial diseases, such as pain. English Multidisciplinary Digital Publishing Institute (MDPI) Development of Dibenzothiazepine Derivatives as Multifunctional Compounds for Neuropathic Pain Article 10.3390/ph15040407 1 Pharmaceuticals, v.15, no.4 Pharmaceuticals 15 4 Y scie scopus 000786919800001 Chemistry, Medicinal Pharmacology & Pharmacy Pharmacology & Pharmacy Article INTRATHECAL TIANEPTINE ANTIDEPRESSANT DISCOVERY ALLODYNIA DIAGNOSIS SEROTONIN BURDEN MODEL neuropathic pain multifunctional compound multiple mechanisms of action tianeptine opioid receptor neurotransmitter transporter